Aims: To investigate health-related quality of life (HRQoL) in short children born small for gestational age (SGA) during growth hormone (GH) treatment and additional postponement of puberty by gonadotropin-releasing hormone analogue (GnRHa). Methods: HRQoL was studied longitudinally during 2 years of treatment in 97 short SGA children (mean age 11.6 years at start). The children were divided into three groups: prepubertal GH-treated (prep-GH) children, pubertal GH-treated (pub-GH) children, and pubertal GH-treated children with additional GnRHa treatment (pub-GH/GnRHa). HRQoL was measured by generic (TACQOL) and short stature-specific (TACQOL-S) questionnaires. Results: The TACQOL-S showed that prep-GH children experienced significant HRQoL improvement on the subscales ‘contact with adults’, ‘body image’ and ‘vitality’, and pub-GH/GnRHa children on the subscales ‘contact with adults’, ‘contact with peers’ and ‘physical abilities’. Parents of prep-GH and pub-GH/GnRHa children reported significant HRQoL improvement on most TACQOL-S scales, whereas HRQoL improvement in pub-GH children reached significance for ‘future prospects’ only. The HRQoL gain was similar in the three groups, also after correction for confounders. The generic questionnaire TACQOL did not reveal any changes. Conclusions: HRQoL improved in prepubertal and pubertal short SGA children during GH treatment. Additional GnRHa treatment had no adverse effect on the HRQoL gain. Disorder-specific questionnaires were particularly appropriate to evaluate HRQoL in children treated for short stature.

Keywords:
Quality of life, Short stature, Small for gestational age, Clinical trial, Growth hormone, Gonadotropin-releasing hormone analogue
1.
Sas T, de Waal W, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A: Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab 1999;84:3064–3070.
2.
Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A: Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab 2003;88:3584–3590.
3.
Dahlgren J, Albertsson-Wikland K: Final height in short children born small for gestational age treated with growth hormone. Pediatr Res 2005;57:216–222.
4.
Carel JC, Chatelain P, Rochiccioli P, Chaussain JL: Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study. J Clin Endocrinol Metab 2003;88:1587–1593.
5.
Nilsson O, Baron J: Fundamental limits on longitudinal bone growth: growth plate senescence and epiphyseal fusion. Trends Endocrinol Metab 2004;15:370–374.
6.
US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological Health: Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79.
7.
Sandberg DE, Colsman M: Growth hormone treatment of short stature: status of the quality of life rationale. Horm Res 2005;63:275–283.
8.
Christensen TL, Djurhuus CB, Clayton P, Christiansen JS: An evaluation of the relationship between adult height and health-related quality of life in the general UK population. Clin Endocrinol (Oxf) 2007;67:407–412.
9.
Bannink EM, Djurhuus CB, Christensen T, Jons K, Hokken-Koelega A: Adult height and health-related quality of life after growth hormone therapy in small for gestational age subjects. J Med Econ 2010;13:221–227.
10.
Bannink EM, van Pareren YK, Theunissen NC, Raat H, Mulder PG, Hokken-Koelega AC: Quality of life in adolescents born small for gestational age: does growth hormone make a difference? Horm Res 2005;64:166–174.
11.
Loftus J, Heatley R, Walsh C, Dimitri P: Systematic review of the clinical effectiveness of Genotropin (somatropin) in children with short stature. J Pediatr Endocrinol Metab 2010;23:535–551.
12.
Visser-van Balen H, Geenen R, Looij J, Huisman J, Wit JM, Sinnema G: The views of young adults and their parents on hormone treatment for short stature in adolescence. Horm Res 2008;69:172–179.
13.
Visser-van Balen H, Geenen R, Moerbeek M, Stroop R, Kamp GA, Huisman J, Wit JM, Sinnema G: Psychosocial functioning of adolescents with idiopathic short stature or persistent short stature born small for gestational age during three years of combined growth hormone and gonadotropin-releasing hormone agonist treatment. Horm Res 2005;64:77–87.
14.
Usher R, McLean F: Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr 1969;74:901–910.
15.
Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170–179.
16.
Cavallo A, Zhou XH: LHRH test in the assessment of puberty in normal children. Horm Res 1994;41:10–15.
17.
Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM: Continuing positive secular growth change in The Netherlands 1955–1997. Pediatr Res 2000;47:316–323.
18.
Vogels T, Verrips GH, Verloove-Vanhorick SP, Fekkes M, Kamphuis RP, Koopman HM, Theunissen NC, Wit JM: Measuring health-related quality of life in children: the development of the TACQOL parent form. Qual Life Res 1998;7:457–465.
19.
Verrips EGH, Vogels TGC, Koopman HM, Theunissen NCM, Kamphuis RP, Fekkes M, Wit JM, Verloove-Vanhorick SP: Measuring health-related quality of life in a child population. Eur J Public Health 1999;9:188–193.
20.
Cronbach LJ, Meehl PE: Construct validity in psychological tests. Psychol Bull 1955;52:281–302.
21.
Guillemin F, Bombardier C, Beaton D: Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417–1432.
22.
Fredriks AM, van Buuren S, Burgmeijer RJF: Growth Diagrams, ed 2 (in Dutch). Houten, Bohn Stafleu van Loghum, 2002.
23.
Verweij A: Dutch Standard Classification of Education. RIVM, Nationaal Kompas Volksgezondheid, The Netherlands, 2008.
24.
Larroque B, Bertrais S, Czernichow P, Leger J: School difficulties in 20-year-olds who were born small for gestational age at term in a regional cohort study. Pediatrics 2001;108:111–115.
25.
Lundgren EM, Cnattingius S, Jonsson B, Tuvemo T: Birth characteristics and different dimensions of intellectual performance in young males: a nationwide population-based study. Acta Paediatr 2003;92:1138–1143.
26.
McCarton CM, Wallace IF, Divon M, Vaughan HG Jr: Cognitive and neurologic development of the premature, small for gestational age infant through age 6: comparison by birth weight and gestational age. Pediatrics 1996;98:1167–1178.
27.
McCormick MC, Workman-Daniels K, Brooks-Gunn J: The behavioral and emotional well-being of school-age children with different birth weights. Pediatrics 1996;97:18–25.
28.
van Pareren YK, Duivenvoorden HJ, Slijper FS, Koot HM, Hokken-Koelega AC: Intelligence and psychosocial functioning during long-term growth hormone therapy in children born small for gestational age. J Clin Endocrinol Metab 2004;89:5295–5302.
29.
Chaplin JE, Kristrom B, Jonsson B, Hagglof B, Tuvemo T, Aronson AS, Dahlgren J, Albertsson-Wikland K: Improvements in behaviour and self-esteem following growth hormone treatment in short prepubertal children. Horm Res Paediatr 2011;75:291–303.
30.
Ross JL, Sandberg DE, Rose SR, Leschek EW, Baron J, Chipman JJ, Cassorla FG, Quigley CA, Crowe BJ, Roberts K, Cutler GB Jr: Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo. J Clin Endocrinol Metab 2004;89:4873–4878.
31.
Stephen MD, Varni JW, Limbers CA, Yafi M, Heptulla RA, Renukuntla VS, Bell CS, Brosnan PG: Health-related quality of life and cognitive functioning in pediatric short stature: comparison of growth-hormone-naive, growth-hormone-treated, and healthy samples. Eur J Pediatr 2010;170:351–358.
32.
Theunissen NC, Vogels TG, Koopman HM, Verrips GH, Zwinderman KA, Verloove-Vanhorick SP, Wit JM: The proxy problem: child report versus parent report in health-related quality of life research. Qual Life Res 1998;7:387–397.
33.
Houtzager BA, Grootenhuis MA, Caron HN, Last BF: Sibling self-report, parental proxies, and quality of life: the importance of multiple informants for siblings of a critically ill child. Pediatr Hematol Oncol 2005;22:25–40.
34.
Raat H, Mohangoo AD, Grootenhuis MA: Pediatric health-related quality of life questionnaires in clinical trials. Curr Opin Allergy Clin Immunol 2006;6:180–185.
35.
Theunissen NC, Kamp GA, Koopman HM, Zwinderman KA, Vogels T, Wit JM: Quality of life and self-esteem in children treated for idiopathic short stature. J Pediatr 2002;140:507–515.
36.
Graber JA, Lewinsohn PM, Seeley JR, Brooks-Gunn J: Is psychopathology associated with the timing of pubertal development? J Am Acad Child Adolesc Psychiatry 1997;36:1768–1776.
37.
Kaltiala-Heino R, Marttunen M, Rantanen P, Rimpela M: Early puberty is associated with mental health problems in middle adolescence. Soc Sci Med 2003;57:1055–1064.
38.
Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J, Deal S, de Vries L, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowitz P, Lahlou N, Lee MM, Lee P, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman D, Styne D, Tauber M, Wit JM: Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752–e762.
39.
Hokken-Koelega AC: Timing of puberty and fetal growth. Best Pract Res Clin Endocrinol Metab 2002;16:65–71.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.